MENU
Aim higher

AVVALACT

Lactomezole, a safe and effective eradication therapy for H. Pylori without the use of antibiotics

To develop a product, Lactomezole, as a new innovative standard of care for the management of dyspepsia and first line treatment for H. pylori infection, which is associated with dyspeptic and gastro-intestinal conditions, including gastric cancer. Lactomezole has significant OTC potential, as it will be the first proton pump inhibitor (PPI) plus prebiotic combo that has demonstrated eradication of H. pylori and normalization of GI tract microbiota without the use of antibiotics.
Acronym: 
AVVALACT
Project ID: 
11 089
Ranking: 
121
Cut-off: 
6
Start date: 
04-09-2017
Project Duration: 
36months
Project costs: 
266 800.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Pharmaceuticals/fine chemicals